

e-Table 2: Drugs not recommended for reimbursement by the Common Drug Review process between September 2003 and December 2005

| Drug | Indication | Disease prevalence | Drug cost* | Reason given for decision |
|---|--|--------------------|---------------------------|--|
| Agalsidase-alfa | ERT for Fabry disease | Rare | \$239 000/yr | Clinical significance of the effects on surrogate outcomes is uncertain |
| Agalsidase-beta† | ERT for Fabry disease | Rare | \$291 000/yr | Clinical significance of the effects on surrogate outcomes is uncertain |
| Alefacept | Treatment of chronic plaque psoriasis | Common | — | No RCT comparing drug with other treatments of psoriasis |
| Atomoxetine | Treatment of attention-deficit hyperactivity disorder | Common | — | Not shown to be superior to other, lower-cost drugs |
| Butoconazole nitrate cream | Treatment of vulvovaginal candidiasis | Common | — | Not shown to be superior to less expensive alternative treatments |
| Cinacalcet | Treatment of secondary hyperparathyroidism in chronic kidney disease | Common | \$23 500/yr | Lack of evidence of effect on clinically important outcomes |
| Ciprofloxacin/dexamethasone | Local treatment of otitis media and otitis externa | Common | — | Insufficient evidence of benefit |
| Eletriptan | Acute treatment of migraine | Common | — | Not shown to be more cost-effective than other triptans |
| Gefitinib | Third-line treatment of non-small cell lung cancer | Not known | \$2000/mo | Insufficient evidence of significant clinical benefit |
| Insulin glargine | Treatment of hyperglycemia of diabetes mellitus | Common | — | Not shown to be superior to other, lower-cost insulin preparations |
| Laronidase | ERT of mucopolysaccharidosis type I | Rare | \$900 000/yr | Insufficient evidence of clinical benefit |
| Memantine | Treatment of moderate to severe dementia of the Alzheimer type | Common | — | Insufficient evidence of clinically significant benefit |
| Miglustat | SRT for Gaucher disease | Rare | \$118 000/yr | Inadequate control groups and focus on lab, not clinical, outcomes |
| Mixed amphetamine salts extended release capsules | Treatment of attention-deficit hyperactivity disorder | Common | — | No RCT comparing drug with an active comparator; cost is higher than cost of comparators |
| Norelgestromin/ethinyl estradiol | Contraceptive patch | Common | — | Not shown to be superior to oral contraceptives |
| Quinagolide | Treatment of idiopathic or pituitary adenoma-associated hyperprolactinemia | Rare | — | Not shown to be superior to other, lower-cost drugs |
| Tenofovir disoproxil fumarate | Treatment of HIV-1 infection | Common | \$16.25/d | Not shown to be superior to other, lower-cost antiviral drugs |
| Teriparatide | Treatment of severe osteoporosis | Common | \$14 500 for 18-mo course | Insufficient evidence of significant clinical benefit |
| Treprostinil | Treatment of pulmonary hypertension | Rare | \$70 000/yr | Insufficient evidence of significant clinical benefit |

Source: Canadian Coordinating Office for Health Technology Assessment. Available: www.ccohta.ca/CDR/cdr_recommendations.cfm (accessed 2005 Dec 07).

Note: ERT = enzyme replacement therapy, SRT= substrate reduction therapy, RCT = randomized controlled trial.

*Estimated maximum cost.

†Submitted twice.